BURLINGAME, Calif.--(BUSINESS WIRE)--Reset Therapeutics, the leader in harnessing the power of the body’s internal clocks to discover, develop, and commercialize high-value therapeutics for a variety of disease indications, today announced that it has been awarded a five-year cooperative agreement by the National Institutes of Health (NIH) to develop a new drug to treat narcolepsy. Reset’s award includes up to $1 million in direct funding and access to contracted research services worth at least $10 million over the project’s anticipated five-year period. The award was made through the NIH Blueprint Neurotherapeutics Network, which was established in order to bridge the gap in neuroscience-related drug development between academic and industry research.
